PedAM
Pediatric Disease Annotations & Medicines
| Disease | cystic fibrosis |
| Symptom | C0021311|infections |
| Sentences | 173 |
| PubMedID- 23287542 | Burkholderia cenocepacia may cause serious infections in patients with cystic fibrosis, and this microorganism can be highly transmissible. |
| PubMedID- 22023324 | Burkholderia cenocepacia, a member of the burkholderia cepacia complex, is an opportunistic pathogen that causes devastating infections in patients with cystic fibrosis. |
| PubMedID- 20161732 | P. aeruginosa causes lethal chronic airway infections in patients with cystic fibrosis and bronchiectasis. |
| PubMedID- 23363478 | Pseudomonas aeruginosa is an opportunistic human pathogen and a major cause of chronic infections in individuals with cystic fibrosis (cf). |
| PubMedID- 21106178 | Pseudomonas aeruginosa is a major hospital-associated pathogen that can cause severe infections, most notably in patients with cystic fibrosis or those hospitalized in intensive care units. |
| PubMedID- 24159289 | Pseudomonas cepacia is increasingly identified as a cause of serious chest infections in children with cystic fibrosis. |
| PubMedID- 24454693 | P. aeruginosa is also widely studied as an opportunistic pathogen of plants, animals and humans and in particular, as a pathogen causing persistent and frequently fatal lung infections in patients with cystic fibrosis (cf) 8. |
| PubMedID- 26019629 | It may cause infections, particularly, in patients with cystic fibrosis, bronchiectasis, neutropenia, acquired immune deficiency syndrome (aids), burns and in those with metabolic, haematologic or malignant diseases. |
| PubMedID- 21912685 | Staphylococcus aureus causes chronic, recurrent endobronchial infections of patients with cystic fibrosis (cf) during childhood . |
| PubMedID- 24730990 | Bacteria of the burkholderia cepacia complex are the cause of severe lung infections primarily in patients with cystic fibrosis (cf). |
| PubMedID- 23620120 | Mycobacterium abscessus is an opportunistic mycobacterial species able to cause chronic pulmonary infections in patients with cystic fibrosis but also soft tissue infections in immunocompetent individuals. |
| PubMedID- 23572517 | It also frequently forms chronic infections in the lungs of cystic fibrosis (cf)3 patients. |
| PubMedID- 22208544 | Commercial availability of more than one inhaled antibiotic for the management of chronic pseudomonas aeruginosa lung infections in persons with cystic fibrosis creates a welcome question: can different inhaled therapies be combined to improve patient outcomes. |
| PubMedID- 24614163 | P. aeruginosa is the predominate pathogen in chronic respiratory infections in patients with cystic fibrosis. |
| PubMedID- 20300602 | The opportunistic pathogen pseudomonas aeruginosa is responsible for chronic infections in the airways of cystic fibrosis (cf) patients and for much of the associated morbidity and mortality 1. |
| PubMedID- 25474359 | Burkholderia species infections in patients with cystic fibrosis in british columbia, canada. |
| PubMedID- 25865196 | The opportunistic pathogen pseudomonas aeruginosa causes chronic airway infections in patients with cystic fibrosis (cf), and it is directly associated with the morbidity and mortality connected with this disease. |
| PubMedID- 22558432 | Background: given the polymicrobial nature of pulmonary infections in patients with cystic fibrosis (cf), it is essential to enhance our knowledge on the composition of the microbial community to improve patient management. |
| PubMedID- 22196973 | Pseudomonas aeruginosa is the major pathogen in chronic lung infections of individuals with cystic fibrosis (cf). |
| PubMedID- 20941353 | Such within-species polymicrobial infection have been reported mainly in chronic and/or open infections (pseudomonas aeruginosa infections of lung in cystic fibrosis patients and of burn wounds , staphylococcus epidermidis joint prosthesis infection , lung tuberculosis , . |
| PubMedID- 23802816 | Rationale: the efficacy of inhaled tobramycin on chronic pseudomonas aeruginosa infections in patients with cystic fibrosis (cf) has been established in clinical trials. |
| PubMedID- 19918014 | Potential risk factors for death measured at baseline included age, sex, ethnicity, bmi, pulmonary function, diabetes, respiratory infections, class of cystic fibrosis transmembrane conductance regulator (cftr) alleles, diagnosis of cystic fibrosis by neonatal screening, prior organ transplantation, and other medical interventions as described below. |
| PubMedID- 20829108 | Burkholderia cepacia complex (bcc) is a group of gram-negative pulmonary pathogens associated with life-threatening infections in patients with cystic fibrosis (cf). |
| PubMedID- 24532839 | The identification of novel protein targets could contribute to the development of much needed antimicrobial therapies to treat the chronic infections found in patients with cystic fibrosis. |
| PubMedID- 23533140 | Overproduction of alginate, also known as mucoidy, affords the bacterium protection from the host's defenses and facilitates the establishment of chronic lung infections in individuals with cystic fibrosis. |
| PubMedID- 25706529 | Pseudomonas aeruginosa is one of the major bacterial causes of respiratory infections- in patients with cystic fibrosis (cf), and contributes to acute exacerbations of chronic obstructive pulmonary disease, or bronchiectasis . |
| PubMedID- 24300299 | Mp-376 was developed for the management of cystic fibrosis (cf) patients with chronic respiratory infections due to pseudomonas aeruginosa . |
| PubMedID- 22848443 | Pseudomonas aeruginosa (pa) is a ubiquitous opportunistic pathogen that is especially notorious for causing highly problematic, chronic infections within the lungs of cystic fibrosis (cf) and chronic obstructive pulmonary disease (copd) patients 1. |
| PubMedID- 21204916 | The opportunistic human pathogen, pseudomonas aeruginosa, is a major cause of life-threatening infections in patients with cystic fibrosis. |
| PubMedID- 21939536 | Chimaera organisms contributed equally to respiratory tract infections in patients with cystic fibrosis when compared with m. |
| PubMedID- 22022288 | Aztreonam (for inhalation solution) for the treatment of chronic lung infections in patients with cystic fibrosis: an evidence-based review. |
| PubMedID- 21303421 | Biofilm-associated chronic pseudomonas aeruginosa lung infections in patients with cystic fibrosis are virtually impossible to eradicate with antibiotics because biofilm-growing bacteria are highly tolerant to antibiotics and host defense mechanisms. |
| PubMedID- 23305368 | Furthermore, t3ss-expressing isolates are predominantly found in acute infections rather than in patients with cystic fibrosis, which indicates that t3ss is a detrimental virulence factor particularly in acute infections. |
| PubMedID- 23065264 | The salt-resistant, antimicrobial properties of cap18 and smap29 suggest potential for the treatment of bacterial infections in individuals with cystic fibrosis, who have high levels of sodium chloride in the sweat . |
| PubMedID- 26180799 | This species is responsible for lymphadenopathy in immunocompetent children in spain and france and has recently been associated with pulmonary infections that complicate cases of cystic fibrosis and disseminated coinfections with cytomegalovirus . |
| PubMedID- 24672734 | Pseudomonas aeruginosa is an aerobic gram-negative gammaproteobacterium that causes opportunistic infections, particularly in patients with cystic fibrosis where it results in inflammation and sepsis (reviewed by veesenmeyer et al. |
| PubMedID- 23486248 | B. cenocepacia causes problematic lung infections in people with cystic fibrosis (cf) because it is multi-drug resistant, transmissible and associated with poor clinical outcome (drevinek and mahenthiralingam, 2010). |
| PubMedID- 24527289 | Sequence analysis of clinical isolates obtained from seven cystic fibrosis (cf) patients with chronic infections that were collected over 16.3 years identified loss-of-function mutants for 7 of these 15 genes. |
| PubMedID- 25494960 | The ecotypes isolated from this long-term experimental evolution are similar to those commonly isolated from lung infections of persons with cystic fibrosis (cf) (zlosnik et al. |
| PubMedID- 25118167 | Methicillin-resistant staphylococcus aureus (mrsa) causes chronic pulmonary infections in patients with cystic fibrosis (cf). |
| PubMedID- 23152277 | Authors' conclusions: the current evidence is insufficient to recommend choosing antibiotics based on biofilm antimicrobial susceptibility testing rather than conventional antimicrobial susceptibility testing in the treatment of pseudomonas aeruginosa pulmonary infections in people with cystic fibrosis. |
| PubMedID- 24363931 | Home self-collection of nasal swabs for diagnosis of acute respiratory virus infections in children with cystic fibrosis. |
| PubMedID- 23796134 | Prominent examples of taas are found in burkholderia cepacia complex, a group of bacterial species causing severe infections in patients with cystic fibrosis. |
| PubMedID- 21942255 | All approved antimicrobial agents for administration by inhalation are indicated for pseudomonas aeruginosa infections in patients with cystic fibrosis. |
| PubMedID- 20093293 | Pseudomonas aeruginosa is the major aetiological agent of chronic pulmonary infections in patients with cystic fibrosis (cf). |
| PubMedID- 24737619 | Why is a healthy person protected from pseudomonas aeruginosa infections, while individuals with cystic fibrosis or damaged epithelium are particularly susceptible to this opportunistic pathogen. |
| PubMedID- 24709961 | These strains are genetically diverse, differ from strains that cause chronic lung infections in patients with cystic fibrosis, and exhibit heterogeneous production of virulence factors in vitro. |
| PubMedID- 23943728 | Background: the paranasal sinuses can be a bacterial reservoir for pulmonary infections in patients with cystic fibrosis (cf) methodology: in this prospective, non-randomised, uncontrolled, intervention cohort study, the clinical effect of sinus surgery followed by two weeks` intravenous antibiotics, 6 months` antibiotic nasal irrigations was assessed in 106 cf patients. |
| PubMedID- 19805554 | The results of the study show that the high concentrations of levofloxacin readily achievable in the lung following aerosol delivery may be useful for the management of pulmonary infections in patients with cystic fibrosis. |
| PubMedID- 24068273 | The objective of this review was to address current concepts related to the clinical impact, diagnosis, and treatment of pseudomonas aeruginosa infections in patients with cystic fibrosis. |